In the family of the nine mammalian enzymes that modify proteins by adding one or two methyl groups to the terminal guanidino nitrogen atoms of acceptor proteins, PRMT7 is unique in producing solely monomethylarginine (MMA) products. The other eight PRMTs catalyze the formation of symmetrically or asymmetrically dimethylated arginine (SDMA or ADMA) residues. Since these modifications are often recognized by reader proteins specific for MMA, SDMA, or ADMA, the biological functions of PRMTs are closely linked to the type of methylation. SDMA and ADMA residues on certain proteins have been known to up‐regulate or down‐regulate transcription, suggesting a possible regulatory function for MMA markers produced by PRMT7. In order to understand the nature of monomethylation and what keeps PRMT7 from dimethylating its substrates, we have focused our attention on the residues of its active site from the protozoan Trypanosoma brucei responsible for sleeping sickness in humans. By using site‐directed mutagenesis, we have mutated several residues including those in the “double E” loop known to interact with the methyl‐accepting substrate arginine residues and then assayed its level and type of methylation via high resolution cation exchange chromatography. Here we present results suggesting that most of these enzyme modifications result in significantly reduced activity but no change in MMA specificity. However, we have found that a mutation of glutamate‐181 (a double E residue) to an aspartate residue not only significantly diminishes enzyme activity but also confers to the enzyme the ability to asymmetrically dimethylate arginines, generating ADMA products. This result pinpoints a crucial residue in maintaining the specificity of PRMT7.Support or Funding InformationEWD was a Frey Fellow of the Damon Runyon Cancer Research Foundation. This work was also supported by grants from NIH including GM026020 (S.G.C.) and a Ruth L. Kirschstein National Service Award GM007185 (to K.J. and R.A.W.).
Read full abstract